Advancing Biotherapeutic Intelligence
Gain access to a vault of next-generation antibody assets to streamline your path to the clinic
Taking aim and focused on clinical success
Talem Therapeutics is focused on the discovery and development of therapeutic antibodies targeting infectious diseases, immuno-oncology, oncology, ophthalmology and vascular disease. With direct access to world-class, expedited, end-to-end technologies, Talem aims to accelerate preclinical development of novel therapeutic antibody treatments to the clinic through strategic alliances and partnerships.
Take your biotherapeutic programs to the next-level
Accelerating development of novel, high-priority, antibody therapies
Explore the innovative options available for out-licensing
Talem antibody experts match high value targets to fully vetted, premium therapeutic antibody programs.
Select from key targets for multiple indications, for licensing:
- From early-stage (discovery level) to IND-enabling programs
- A broad range of indications: immuno-oncology, oncology, ophthalmology, immunology, and infectious, and vascular diseases
Empower therapeutic innovation with AI
Explore how AI-driven solutions at Talem Therapeutics are advancing antibody development. Contact us to learn how our optimized assets can accelerate your journey to clinical success.
Join us at an upcoming event
Join us at top-tier industry events below. Whether you’re seeking knowledge, partnerships, or simply looking for the latest innovations driving next-gen pharma solutions, let’s start the collaborative discussion. Don’t miss this opportunity to be part of the forefront of novel therapeutic advancements.